Joseph (Joe) Schwartz

“You now have a larger cohort of patients with sufficient time on therapy to begin evaluating refill behavior. What can you share about persistence, refill timing, discontinuations, and adherence, and how are those things tracking relative to the assumptions you shared with us previously?”

“Hypothetically, if the FDA doesn't budge, does Vantage PBC have any ability to strengthen the Volixabat regulatory package for PSC? For instance, if a filing in PBC is an NDA and a filing in PSC is an SNDA, could that order of operations be successful without about having to do another phase three?”

“We appreciate you joining at such an important time. I look forward to seeing how you shape the company's future. For the next SRP 1001 and 1003 updates. What quantitative benchmarks does each program need to clear to justify pivotal advancement rather than continued exploration?”

“For FSGS, what did you learn in the first full quarter post-approval about where demand is coming from the most in terms of prescribers and the patients they're prescribing, Phil Spari, too?”

“I wanted to ask about the potential read-through from trailhead to base camp. Have you done any more response exposure analyses? And are the two patients, I think there were one in three, who had the greatest improvement in MRI fat fraction, the same two who had the greatest improvement in TEC99C?”